Published in Mol Ther on January 15, 2008
T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32
A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood (2009) 2.25
Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev (2009) 1.65
Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res (2008) 1.65
Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference. J Virol (2007) 1.50
Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. Gene Ther (2008) 1.32
Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo. Gene Ther (2009) 1.27
Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. Mol Ther (2009) 1.25
MicroRNAs and human retroviruses. Biochim Biophys Acta (2011) 1.23
Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol Ther (2009) 1.18
Independent and high-level dual-gene expression in adult stem-progenitor cells from a single lentiviral vector. Gene Ther (2009) 1.13
Dicer-independent processing of short hairpin RNAs. Nucleic Acids Res (2013) 1.06
CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape. Mol Ther (2016) 1.06
Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs. Retrovirology (2010) 1.05
Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice. PLoS One (2012) 1.01
Potent microRNA suppression by RNA Pol II-transcribed 'Tough Decoy' inhibitors. RNA (2012) 1.00
Genetically encoding unnatural amino acids in neural stem cells and optically reporting voltage-sensitive domain changes in differentiated neurons. Stem Cells (2011) 0.99
Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes. Mol Ther (2012) 0.98
Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy. Mol Ther (2010) 0.98
Evolutionary analysis of human immunodeficiency virus type 1 therapies based on conditionally replicating vectors. PLoS Comput Biol (2012) 0.97
The efficacy of generating three independent anti-HIV-1 siRNAs from a single U6 RNA Pol III-expressed long hairpin RNA. PLoS One (2008) 0.96
Efficient viral delivery system for unnatural amino acid mutagenesis in mammalian cells. Proc Natl Acad Sci U S A (2013) 0.96
Simultaneous knockdown of the expression of two genes using multiple shRNAs and subsequent knock-in of their expression. Nat Protoc (2009) 0.96
Antiviral RNAi: translating science towards therapeutic success. Pharm Res (2011) 0.94
Preclinical in vivo evaluation of the safety of a multi-shRNA-based gene therapy against HIV-1. Mol Ther Nucleic Acids (2013) 0.93
Creating genetic resistance to HIV. Curr Opin Immunol (2012) 0.93
Current progress in the development of RNAi-based therapeutics for HIV-1. Gene Ther (2011) 0.93
Titers of lentiviral vectors encoding shRNAs and miRNAs are reduced by different mechanisms that require distinct repair strategies. RNA (2010) 0.92
VIRsiRNAdb: a curated database of experimentally validated viral siRNA/shRNA. Nucleic Acids Res (2011) 0.92
HIVsirDB: a database of HIV inhibiting siRNAs. PLoS One (2011) 0.91
Efficient siRNA delivery by the cationic liposome DOTAP in human hematopoietic stem cells differentiating into dendritic cells. J Biomed Biotechnol (2009) 0.91
Optimization of linear double-stranded RNA for the production of multiple siRNAs targeting hepatitis C virus. RNA (2009) 0.90
HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms. Philos Trans R Soc Lond B Biol Sci (2010) 0.90
Probing the shRNA characteristics that hinder Dicer recognition and consequently allow Ago-mediated processing and AgoshRNA activity. RNA (2014) 0.89
Silencing early viral replication in macrophages and dendritic cells effectively suppresses flavivirus encephalitis. PLoS One (2011) 0.89
A versatile modular vector system for rapid combinatorial mammalian genetics. J Clin Invest (2015) 0.89
Efficient downregulation of multiple mRNA targets with a single shRNA-expressing lentiviral vector. Plasmid (2010) 0.87
Multiple shRNA combinations for near-complete coverage of all HIV-1 strains. AIDS Res Ther (2011) 0.87
Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1. BioDrugs (2012) 0.87
RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther (2010) 0.87
RNAi-mediated inhibition of HIV-1 by targeting partially complementary viral sequences. Nucleic Acids Res (2009) 0.86
In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy. Retrovirology (2010) 0.86
Deriving four functional anti-HIV siRNAs from a single Pol III-generated transcript comprising two adjacent long hairpin RNA precursors. Nucleic Acids Res (2010) 0.86
Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success. Virol J (2009) 0.86
Optimized lentiviral vectors for HIV gene therapy: multiplexed expression of small RNAs and inclusion of MGMT(P140K) drug resistance gene. Mol Ther (2014) 0.85
An infinitely expandable cloning strategy plus repeat-proof PCR for working with multiple shRNA. PLoS One (2008) 0.85
Efficient inhibition of HIV-1 replication by an artificial polycistronic miRNA construct. Virol J (2012) 0.83
Modified gateway system for double shRNA expression and Cre/lox based gene expression. BMC Biotechnol (2011) 0.83
Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral Vectors. Acta Naturae (2013) 0.83
RNA polymerase III can drive polycistronic expression of functional interfering RNAs designed to resemble microRNAs. Nucleic Acids Res (2009) 0.82
Selection of RNAi-based inhibitors for anti-HIV gene therapy. World J Virol (2012) 0.81
Selection of potent non-toxic inhibitory sequences from a randomized HIV-1 specific lentiviral short hairpin RNA library. PLoS One (2010) 0.81
RNAi-Mediated CCR5 Knockdown Provides HIV-1 Resistance to Memory T Cells in Humanized BLT Mice. Mol Ther Nucleic Acids (2015) 0.81
Multigenic lentiviral vectors for combined and tissue-specific expression of miRNA- and protein-based antiangiogenic factors. Mol Ther Methods Clin Dev (2015) 0.81
Gene therapy strategies for HIV/AIDS: preclinical modeling in humanized mice. Viruses (2013) 0.80
A direct comparison of strategies for combinatorial RNA interference. BMC Mol Biol (2010) 0.80
Bone Marrow Gene Therapy for HIV/AIDS. Viruses (2015) 0.79
Multiplexing seven miRNA-Based shRNAs to suppress HIV replication. Mol Ther (2014) 0.79
E6 and E7 gene silencing results in decreased methylation of tumor suppressor genes and induces phenotype transformation of human cervical carcinoma cell lines. Oncotarget (2015) 0.79
Expression of multiple artificial microRNAs from a chicken miRNA126-based lentiviral vector. PLoS One (2011) 0.79
The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy. Gene Ther (2015) 0.79
Optimization of Critical Hairpin Features Allows miRNA-based Gene Knockdown Upon Single-copy Transduction. Mol Ther Nucleic Acids (2014) 0.79
A comparison of multiple shRNA expression methods for combinatorial RNAi. Genet Vaccines Ther (2011) 0.79
The impact of unprotected T cells in RNAi-based gene therapy for HIV-AIDS. Mol Ther (2013) 0.78
Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS. Adv Drug Deliv Rev (2016) 0.78
Sources of Error in Mammalian Genetic Screens. G3 (Bethesda) (2016) 0.78
Stem cell-based therapies for HIV/AIDS. Adv Drug Deliv Rev (2016) 0.77
Directed HIV-1 evolution of protease inhibitor resistance by second-generation short hairpin RNAs. Antimicrob Agents Chemother (2011) 0.77
Towards Antiviral shRNAs Based on the AgoshRNA Design. PLoS One (2015) 0.77
Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy. J Investig Med (2014) 0.76
New insights into inhibition of human immunodeficiency virus type 1 replication through mutant tRNALys3. Retrovirology (2013) 0.76
Controlling HIV-1: Non-Coding RNA Gene Therapy Approaches to a Functional Cure. Front Immunol (2015) 0.76
Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy Approach. Mol Ther Nucleic Acids (2016) 0.76
Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir? Immunotherapy (Los Angel) (2015) 0.75
Achieving HIV-1 Control through RNA-Directed Gene Regulation. Genes (Basel) (2016) 0.75
Efficient inhibition of human immunodeficiency virus replication using novel modified microRNA-30a targeting 3'-untranslated region transcripts. Exp Ther Med (2016) 0.75
Non-coding RNAs: Bridging Biology and Therapy. J RNAi Gene Silencing (2009) 0.75
Evaluation of a combinatorial RNAi lentivirus vector targeting foot-and-mouth disease virus in vitro and in vivo. Mol Med Rep (2015) 0.75
Bolaamphiphiles as carriers for siRNA delivery: From chemical syntheses to practical applications. J Control Release (2015) 0.75
Identification of a new human coronavirus. Nat Med (2004) 11.24
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2002) 3.59
Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23
HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res (2005) 2.93
Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS (2004) 2.51
Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther (2006) 2.48
The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog (2007) 2.48
Suppression of RNA interference by adenovirus virus-associated RNA. J Virol (2005) 2.29
A novel pancoronavirus RT-PCR assay: frequent detection of human coronavirus NL63 in children hospitalized with respiratory tract infections in Belgium. BMC Infect Dis (2005) 2.28
Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A (2005) 2.21
RNA interference against viruses: strike and counterstrike. Nat Biotechnol (2007) 2.14
Viral evolution as a tool to improve the tetracycline-regulated gene expression system. J Biol Chem (2004) 2.06
In HIV-1 pathogenesis the die is cast during primary infection. AIDS (2007) 2.04
Croup is associated with the novel coronavirus NL63. PLoS Med (2005) 2.03
Detection of new viruses by VIDISCA. Virus discovery based on cDNA-amplified fragment length polymorphism. Methods Mol Biol (2008) 1.95
Retroviral superinfection resistance. Retrovirology (2005) 1.82
A novel long distance base-pairing interaction in human immunodeficiency virus type 1 RNA occludes the Gag start codon. J Biol Chem (2002) 1.81
Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J Virol (2002) 1.78
The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle. J Virol (2003) 1.71
Inhibition of virus replication by RNA interference. J Biomed Sci (2003) 1.70
Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res (2008) 1.65
Factor correction as a tool to eliminate between-session variation in replicate experiments: application to molecular biology and retrovirology. Retrovirology (2006) 1.64
Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol (2004) 1.64
Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol (2008) 1.61
The novel human coronaviruses NL63 and HKU1. J Virol (2006) 1.59
Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol (2004) 1.53
Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol (2007) 1.52
Multiple secondary structure rearrangements during HIV-1 RNA dimerization. Biochemistry (2002) 1.50
Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference. J Virol (2007) 1.50
Microprocessor, Setx, Xrn2, and Rrp6 co-operate to induce premature termination of transcription by RNAPII. Cell (2012) 1.49
The tRNA primer activation signal in the human immunodeficiency virus type 1 genome is important for initiation and processive elongation of reverse transcription. J Virol (2002) 1.40
Mosaic structure of human coronavirus NL63, one thousand years of evolution. J Mol Biol (2006) 1.40
Proteomic studies reveal coordinated changes in T-cell expression patterns upon infection with human immunodeficiency virus type 1. J Virol (2008) 1.40
Genome structure and transcriptional regulation of human coronavirus NL63. Virol J (2004) 1.39
Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology (2013) 1.37
Human coronavirus NL63, a new respiratory virus. FEMS Microbiol Rev (2006) 1.37
Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology (2010) 1.36
The HIV-1 leader RNA conformational switch regulates RNA dimerization but does not regulate mRNA translation. Biochemistry (2005) 1.36
Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. J Virol (2004) 1.34
Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. J Clin Invest (2005) 1.34
Lack of detection of XMRV in seminal plasma from HIV-1 infected men in The Netherlands. PLoS One (2010) 1.34
Deep sequencing of virus-infected cells reveals HIV-encoded small RNAs. Nucleic Acids Res (2011) 1.32
A miRNA-tRNA mix-up: tRNA origin of proposed miRNA. RNA Biol (2010) 1.30
A riboswitch regulates RNA dimerization and packaging in human immunodeficiency virus type 1 virions. J Virol (2004) 1.30
Human parechovirus type 1, 3, 4, 5, and 6 detection in picornavirus cultures. J Clin Microbiol (2007) 1.28
A systematic analysis of the effect of target RNA structure on RNA interference. Nucleic Acids Res (2007) 1.27
Dimerization and template switching in the 5' untranslated region between various subtypes of human immunodeficiency virus type 1. J Virol (2003) 1.26
Differential susceptibility of naïve, central memory and effector memory T cells to dendritic cell-mediated HIV-1 transmission. Retrovirology (2006) 1.23
Comparison of single regulated lentiviral vectors with rtTA expression driven by an autoregulatory loop or a constitutive promoter. Nucleic Acids Res (2005) 1.23
The TAR hairpin of human immunodeficiency virus type 1 can be deleted when not required for Tat-mediated activation of transcription. J Virol (2007) 1.22
RNA structure modulates splicing efficiency at the human immunodeficiency virus type 1 major splice donor. J Virol (2007) 1.22
Selection of T1249-resistant human immunodeficiency virus type 1 variants. J Virol (2008) 1.21
Sialoadhesin (CD169) expression in CD14+ cells is upregulated early after HIV-1 infection and increases during disease progression. PLoS One (2007) 1.21
The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference. Retrovirology (2006) 1.20
Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr (2008) 1.20
Regulated HIV-2 RNA dimerization by means of alternative RNA conformations. Nucleic Acids Res (2002) 1.20
Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands. PLoS One (2009) 1.20
Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol (2006) 1.19
Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN--gp120 interaction. J Virol (2005) 1.19
RNAi suppressors encoded by pathogenic human viruses. Int J Biochem Cell Biol (2008) 1.18
Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol Ther (2009) 1.18
Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One (2009) 1.16
HIV-1 latency in actively dividing human T cell lines. Retrovirology (2008) 1.16
Effects of random mutations in the human immunodeficiency virus type 1 transcriptional promoter on viral fitness in different host cell environments. J Virol (2006) 1.16
Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis (2012) 1.13
The NS3 protein of rice hoja blanca virus complements the RNAi suppressor function of HIV-1 Tat. EMBO Rep (2009) 1.13
Inhibition of HIV-1 by fusion inhibitors. Curr Pharm Des (2010) 1.13
Probing alternative foldings of the HIV-1 leader RNA by antisense oligonucleotide scanning arrays. Nucleic Acids Res (2004) 1.12
Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J Biol Chem (2009) 1.11
SHAPE-directed discovery of potent shRNA inhibitors of HIV-1. Mol Ther (2012) 1.11
The biased nucleotide composition of the HIV genome: a constant factor in a highly variable virus. Retrovirology (2012) 1.10
Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J Virol (2008) 1.10
The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology (2008) 1.10
Triple HIV-1 infection. N Engl J Med (2005) 1.09
Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol (2011) 1.09
Antibacterial and antiviral effects of milk proteins and derivatives thereof. Curr Pharm Des (2003) 1.08
Survey of the temporal changes in HIV-1 replicative fitness in the Amsterdam Cohort. Virology (2007) 1.08
RNAi and cellular miRNAs in infections by mammalian viruses. Methods Mol Biol (2011) 1.08
Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother (2006) 1.07
Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site. J Virol (2006) 1.07
Dicer-independent processing of short hairpin RNAs. Nucleic Acids Res (2013) 1.06
Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure. AIDS Res Hum Retroviruses (2004) 1.06
Design of extended short hairpin RNAs for HIV-1 inhibition. Nucleic Acids Res (2007) 1.06
The HIV RNA setpoint theory revisited. Retrovirology (2007) 1.06
A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs. J RNAi Gene Silencing (2005) 1.06
Long-term inhibition of HIV-1 replication with RNA interference against cellular co-factors. Antiviral Res (2010) 1.05
Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs. Retrovirology (2010) 1.05
HIV-1 drug-resistance and drug-dependence. Retrovirology (2007) 1.05
A conditionally replicating virus as a novel approach toward an HIV vaccine. Methods Enzymol (2004) 1.05
Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. J Virol (2011) 1.04
Opposing roles of blood myeloid and plasmacytoid dendritic cells in HIV-1 infection of T cells: transmission facilitation versus replication inhibition. Blood (2006) 1.04
An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection. J Virol (2012) 1.04
Identification of new human coronaviruses. Expert Rev Anti Infect Ther (2007) 1.04
HIV-1 reverse transcription initiation: a potential target for novel antivirals? Virus Res (2008) 1.03
Occult hepatitis B infection: an evolutionary scenario. Virol J (2008) 1.03